Preliminary structure - Activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 4093-4103

  Onajole, Oluseye K ^a   Pieroni, Marco ^a,e   Tipparaju, Suresh K ^a,f   Lun, Shichun ^b   Stec, Jozef ^a,g   Chen, Gang ^a   Gunosewoyo, Hendra ^a   Guo, Haidan ^b   Ammerman, Nicole C ^b,c   Bishai, William R ^b,c,d   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e UNIVERSITY OF PARMA   (Italy)

^f MERRIMACK PHARMACEUTICALS   (United States)

^g CHICAGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; INDOLE 2 CARBOXAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; VERO CELL;

ANIMALS; ANTITUBERCULAR AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COLONY COUNT, MICROBIAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; INDOLES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SERUM BACTERICIDAL TEST; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS;

EID: 84878098841     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4003878     Document Type: Article

References (32)

1. Tuberculosis; Fact Sheet no. 104; World Health Organisation: Geneva, 2013; http://www.who.int/mediacentre/factsheets/fs104/en/index.html (accessed February 11, 2013).
2. Global Tuberculosis Report 2012; World Health Organisation: Geneva, 2012; http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf (accessed January 8, 2013).
3. Ying, Z. The magic bullets and tuberculosis drug targets Annu. Rev. Pharmacol. Toxicol. 2005, 529-564
4. Ormerod, L. P. Directly observed therapy (DOT) for tuberculosis: why, when, how and if? Thorax 1999, 54, S42-S45
5. Jassal, M. S.; Bishai, W. R. Epidemiology and Challenges to the Elimination of Global Tuberculosis Clin. Infect. Dis. 2010, 50, S156-S164
6. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis Nature 2011, 469, 483-490
7. Drug Pipeline; Working Group on New TB Drugs, 2013; http://www. newtbdrugs.org/pipeline.php (accessed January 25, 2013).
8. Lienhardt, C.; Vernon, A.; Raviglione, M. C. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Curr. Opin. Pulm. Med. 2010, 16, 186-193
9. Ma, Z.; Lienhardt, C.; McIlleron, H.; Nunn, A. J.; Wang, X. Global tuberculosis drug development pipeline: the need and the reality Lancet 2010, 375, 2100-2109
10. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H. W. H.; Neefs, J. M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 2005, 307, 223-227
11. Lenaerts, A. J.; Gruppo, V.; Marietta, K. S.; Johnson, C. M.; Driscoll, D. K.; Tompkins, N. M.; Rose, J. D.; Reynolds, R. C.; Orme, I. M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob. Agents Chemother. 2005, 49, 2294-2301
12. Schecter, G. F.; Scott, C.; True, L.; Raftery, A.; Flood, J.; Mase, S. Linezolid in the Treatment of Multidrug-Resistant Tuberculosis Clin. Infect. Dis. 2010, 50, 49-55
13. Shandil, R. K.; Jayaram, R.; Kaur, P.; Gaonkar, S.; Suresh, B. L.; Mahesh, B. N.; Jayashree, R.; Nandi, V.; Bharath, S.; Balasubramanian, V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy Antimicrob. Agents Chemother. 2007, 51, 576-582
14. Rosenthal, I. M.; Zhang, M.; Williams, K. N.; Peloquin, C. A.; Tyagi, S.; Vernon, A. A.; Bishai, W. R.; Chaisson, R. E.; Grosset, J. H.; Nuermberger, E. L. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model PLoS Med. 2007, 4, 1931-1939
15. FDA News Release; United States Food and Drug Administration: Silver Spring, MD, Dec 31, 2012; www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm333695.htm (accessed January 14, 2013).
16. Mao, J.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. HTS, chemical hybridization, and drug design identify a chemically unique antituberculosis agent-coupling serendipity and rational approaches to drug discovery ChemMedChem 2007, 2, 811-813
17. Mao, J.; Wang, Y.; Wan, B.; Kozikowski, A. P.; Franzblau, S. G. Design, synthesis, and pharmacological evaluation of mefloquine-based ligands as novel antituberculosis agents ChemMedChem 2007, 2, 1624-1630
18. Pieroni, M.; Lilienkampf, A.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. Synthesis, Biological Evaluation, and Structure-Activity Relationships for 5-[(E)-2-Arylethenyl]-3-isoxazolecarboxylic Acid Alkyl Ester Derivatives as Valuable Antitubercular Chemotypes J. Med. Chem. 2009, 52, 6287-6296
19. Lilienkampf, A.; Mao, J.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. Structure-Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating Mycobacterium tuberculosis J. Med. Chem. 2009, 52, 2109-2118
20. Lilienkampf, A.; Pieroni, M.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. Rational Design of 5-Phenyl-3-isoxazolecarboxylic Acid Ethyl Esters as Growth Inhibitors of Mycobacterium tuberculosis. A Potent and Selective Series for Further Drug Development J. Med. Chem. 2010, 53, 678-688
21. Pieroni, M.; Lilienkampf, A.; Wang, Y.; Wan, B.; Cho, S.; Franzblau, S. G.; Kozikowski, A. P. NOC Chemistry for Tuberculosis-Further Investigations on the Structure-Activity Relationships of Antitubercular Isoxazole-3-carboxylic Acid Ester Derivatives ChemMedChem 2010, 5, 1667-1672
22. Pieroni, M.; Tipparaju, S. K.; Lun, S.; Song, Y.; Sturm, A. W.; Bishai, W. R.; Kozikowski, A. P. Pyrido[1,2- a ]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB ChemMedChem 2011, 6, 334-342
23. Collins, L. A.; Franzblau, S. G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997, 41, 1004-1009
24. Lun, S.; Guo, H.; Onajole, O. K.; Pieroni, M.; Gunosewoyo, H.; Chen, G.; Tipparaju, S. K.; Ammerman, N. C.; Kozikowski, A. P.; Bishai, W. R. Identification of a new molecular class active against Mycobacterium tuberculosis. Unpublished results.
25. Kurdukar, R.; Subba Rao, N. V. Physiologically active compounds. VII. Synthesis of halo and nitro coumarones Proc. Indian Acad. Sci., Sect. A 1963, 58, 336-342
26. Dean, F. M.; Halewood, P.; Mongkolsuk, S.; Robertson, A.; Whalley, W. B. Usnic Acid. Part IX. A revised Structure for Usnolic Acid and the Resolution of Usnic Acid J. Chem. Soc. 1953, 1250-1261
27. Suzuki, T.; Horaguchi, T.; Shimizu, T.; Abe, T. Benzofuran Derivatives 0.1. On the Effects of Substituents in Benzofuran Syntheses Bull. Chem. Soc. Jpn. 1983, 56, 2762-2767
28. Li, J. C.; Rush, T. S.; Li, W.; DeVincentis, D.; Du, X. M.; Hu, Y. H.; Thomason, J. R.; Xiang, J. S.; Skotnicki, J. S.; Tam, S.; Cunningham, K. M.; Chockalingam, P. S.; Morris, E. A.; Levin, J. I. Synthesis and SAR of highly selective MMP-13 inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 4961-4966
29. Ballell, L.; Bates, R. H.; Young, R. J.; Alvarez-Gomez, D.; Alvarez-Ruiz, E.; Barroso, V.; Blanco, D.; Crespo, B.; Escribano, J.; Gonzalez, R.; Lozano, S.; Huss, S.; Santos-Villarejo, A.; Julio Martin-Plaza, J.; Mendoza, A.; Jose Rebollo-Lopez, M.; Remuinan-Blanco, M.; Luis Lavandera, J.; Perez-Herran, E.; Javier Gamo-Benito, F.; Francisco Garcia-Bustos, J.; Barros, D.; Castro, J. P.; Cammack, N. Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis ChemMedChem 2013, 8, 313-321
30. Ioerger, T. R.; Koo, S.; No, E.-G.; Chen, X.; Larsen, M. H.; Jacobs, W. R., Jr.; Pillay, M.; Sturm, A. W.; Sacchettini, J. C. Genome Analysis of Multi- and Extensively-Drug-Resistant Tuberculosis from KwaZulu-Natal, South Africa PLoS One 2009, 4, e7778
31. Chopra, S.; Matsuyama, K.; Tran, T.; Malerich, J. P.; Wan, B.; Franzblau, S. G.; Lun, S.; Guo, H.; Maiga, M. C.; Bishai, W. R.; Madrid, P. B. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis J. Antimicrob. Chemother. 2012, 67, 415-421
32. Peterson, L. R.; Shanholtzer, C. J. Tests for Bactericidal Effects of Antimicrobial Agents-Technical Performance and Clinical Relevance Clin. Microbiol. Rev. 1992, 5, 420-432